Frequencies of an Immunogenic HER-2/neu Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer

HER-2/neu is the human epidermal growth factor receptor 2, which is associated with the progression of prostate cancer (PCa). HER-2/neu-specific T cell immunity has been shown to predict immunologic and clinical responses in PCa patients treated with HER-2/neu peptide vaccines. However, its prognost...

Descripción completa

Detalles Bibliográficos
Autores principales: Goulielmaki, Maria, Stokidis, Savvas, Anagnostou, Theodoros, Voutsas, Ioannis F., Gritzapis, Angelos D., Baxevanis, Constantin N., Fortis, Sotirios P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058793/
https://www.ncbi.nlm.nih.gov/pubmed/36983028
http://dx.doi.org/10.3390/ijms24065954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058793/
https://www.ncbi.nlm.nih.gov/pubmed/36983028
http://dx.doi.org/10.3390/ijms24065954

Ejemplares similares